As filed with the Securities and Exchange Commission on August 5, 2020
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE
SECURITIES ACT OF 1933
SANGAMO THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
Delaware
|
|
68-0359556
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
7000 Marina Blvd.
Brisbane, California
|
|
94005
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Amended and Restated Sangamo Therapeutics, Inc. 2018 Equity Incentive Plan
(Full title of the plan)
Alexander D. Macrae
President and Chief Executive Officer
Sangamo Therapeutics, Inc.
7000 Marina Blvd.
Brisbane, California 94005
(510) 970-6000
(Name and address of agent for service) (telephone number, including area code, of agent for service)
Copies to:
Chadwick L. Mills
Cooley LLP
101
California St., 5th Floor
San Francisco, California 94111-5800
Tel: (415) 693-2000
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated
filer, a smaller reporting company or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
Large accelerated filer
|
|
☒
|
|
Accelerated filer
|
|
☐
|
|
|
|
|
Non-accelerated filer
|
|
☐
|
|
Smaller reporting company
|
|
☐
|
|
|
|
|
|
|
|
|
Emerging growth company
|
|
☐
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
CALCULATION
OF REGISTRATION FEE
|
|
|
|
|
|
|
|
|
|
Title of securities
to be registered
|
|
Amount
to be
registered(1)
|
|
Proposed
maximum
offering
price
per share(2)
|
|
Proposed
maximum
aggregate
offering price(2)
|
|
Amount of
registration fee
|
Common Stock, par value $0.01 per share
|
|
9,900,000
|
|
$10.04
|
|
$99,396,000
|
|
$12,901.60
|
|
|
(1)
|
Pursuant to Rule 416 under the Securities Act of 1933, as amended (the Securities Act), this
registration statement shall also cover any additional shares of the Registrants common stock that become issuable under the plan set forth herein by reason of any stock dividend, stock split, recapitalization or other similar transaction
effected without receipt of consideration that increases the number of outstanding shares of the Registrants common stock.
|
(2)
|
Estimated solely for the purposes of calculating the registration fee pursuant to Rule 457(h) and
(c) under the Securities Act. The offering price per share and the aggregate offering price are based on the average of the high and low prices of the Registrants common stock as reported on The Nasdaq Global Select Market on
July 29, 2020.
|